At a glance
ClinicalIndex Comparison RecordN/ACompleted· 76 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study
In Brief
An observational study for Multiple Sclerosis. Completed, enrolled 76 participants across 10 sites.
Detailed Summary
The Main Hypothesis of this extension trial is that among those who have successfully discontinued their DMT as part of the DISCOMS trial (i.e. did not have a new MS relapse or brain MRI lesion) and remain off DMT after DISCOMS are at no greater risk of new or worsened MS disease activity compared to those who successfully continued their DMT as part of DISCOMS and remain on DMT, each assessed at least one year after termination of the primary DISCOMS study.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
CollaboratorsEMD Serono, National Multiple Sclerosis Society
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartMay 2021
Primary CompletionNov 2022
TodayJul 2026
First PostedFeb 15, 2021
Enrollment StartMay 18, 2021
Primary CompletionNov 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.4 years ago